New combo aims to extend control of advanced lung cancer

NCT ID NCT05613413

Recruiting now Disease control Sponsor: University of Illinois at Chicago Source: ClinicalTrials.gov ↗

First seen Jan 11, 2026 · Last updated May 14, 2026 · Updated 14 times

Summary

This study tests whether a combination of two drugs, cabozantinib and pembrolizumab, can help keep advanced squamous non-small cell lung cancer from growing after initial treatment. About 36 adults whose cancer was controlled after standard chemotherapy plus pembrolizumab will receive the drug combo as maintenance therapy. The goal is to see how long the cancer stays stable and to monitor side effects.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC SQUAMOUS NON-SMALL CELL LUNG CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Ryan Nguyen
RECRUITING

Chicago, Illinois, 60612, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

METASTATIC SQUAMOUS NON-SMALL CELL LUNG CARCINOMA